EVerZom
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
45 Rue Des Saints-pères, Paris, Ile-de-F...Phone Number
+33 678280120Website
www.everzom.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About EVerZom
EVerZom is an innovative exosome biotech company focused on developing exosome therapeutics for digestive tissue healing, fistula treatment, and organ regeneration. Founded in 2019, the company aims to revolutionize the therapeutic landscape with its proprietary platform that encompasses the entire technological value chain of exosome production. EVerZom is currently advancing two drug candidates targeting Crohn's fistula and organ regeneration, with promising preclinical results indicating accelerated healing and reduced inflammation. The company seeks to establish partnerships for co-development in various therapeutic areas while addressing significant unmet medical needs in regenerative medicine.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EVerZom your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if EVerZom had a recent Job posting/layoffs
Product Launch: Get notified when EVerZom launches new products
Earning: See what the market has to say on EVerZom recently announced quarterly report
Check out if EVerZom is spiking on competitors!
Funding: Get notified immidiatlly once EVerZom has new funding data
EVerZom, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at EVerZom
Check if EVerZom has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at EVerZom
Find 2 more new buyers
Company Profile Activity
Activity Insights
EVerZom is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EVerZom is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EVerZom.
EVerZom financials insights
Gather financial insights about EVerZom, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Unspecified
$1.3M
EVerZom Tech Stack
A closer look at the technologies used by EVerZom
See more technologies
EVerZom News & Media
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases to launch its first clinical trial of EVerGel™ in 2026.Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technologyEVerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields
EVerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yieldsExclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.
Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EVerZom
Sign Up For FreeTo access detailed company insights
EVerZom is an innovative exosome biotech company focused on developing exosome therapeutics for digestive tissue healing, fistula treatment, and organ regeneration. Founded in 2019, the company aims to revolutionize the therapeutic landscape with its proprietary platform that encompasses the entire technological value chain of exosome production. E... Read More
